Invivyd’s (IVVD) Buy Rating Reiterated at HC Wainwright

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Invivyd in a report on Thursday, March 20th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $7.89.

Invivyd Trading Down 8.9 %

IVVD stock opened at $0.66 on Wednesday. The firm has a market cap of $78.91 million, a PE ratio of -0.34 and a beta of 0.09. The stock has a 50-day moving average price of $0.99 and a 200-day moving average price of $0.86. Invivyd has a 1-year low of $0.35 and a 1-year high of $4.74.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.10. The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $13.57 million. On average, analysts forecast that Invivyd will post -1.64 earnings per share for the current year.

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 86,545 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total transaction of $41,541.60. Following the completion of the sale, the director now directly owns 3,170,231 shares of the company’s stock, valued at $1,521,710.88. The trade was a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 17.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Invivyd

A number of hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its holdings in Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after buying an additional 35,904 shares in the last quarter. Barclays PLC boosted its holdings in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after acquiring an additional 204,188 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Invivyd by 290.5% in the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after acquiring an additional 87,358 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of Invivyd by 1,276.5% in the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after purchasing an additional 282,100 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.